Valentina Mazzotta

Infectious Disease physician; COVID-19, HIV, MPOX specialist; researcher at the National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS in Rome

[Valentina Mazzotta @Vale_Mazzotta]

https://t.co/IFxmHEP23A

[marta camici @MartaCamici]

https://t.co/GueuiomQvl

💥💥💥
In the hope that our perspective on #longcovid can contribute to scientific progress in identifying the right therapeutic target @andreaantinori (figure by my best friend).

[Valentina Mazzotta @Vale_Mazzotta]

Data useful for the evaluation of the persistence of immune response after MVA vaccination #mpox #MVA #monkeypox

Mpox Immune response elicited by MVA-BN vaccine over 12 months of follow-up - Journal of Infection https://t.co/go0Z8yIyHj

[🇪🇺 Andrea Antinori @andreaantinori]

Our preprinted paper on neutralizing and T-cell immune response elicited by #MVA-BN vaccine after one year from vaccination. #mpox #HIV #MPXV ⁦@Vale_Mazzotta⁩ ⁦@WHO⁩ ⁦@ECDC_EU⁩ ⁦@EACSociety⁩ https://t.co/CljlF7E9aT

[🇪🇺 Andrea Antinori @andreaantinori]

Our preprinted paper on comparison between ID and SC delivery of MVA-BN shows that ID route has higher reactogenicity and comparable immunogenicity with significant sparing doses. ⁦@Vale_Mazzotta⁩ ⁦@WHO⁩ ⁦@ECDC_EU⁩ #mpox https://t.co/EHxr4ho9TY

[medRxiv @medrxivpreprint]

Reactogenicity and immunogenicity against MPXV of the intradermal administration of Modified V Vaccinia Ankara compared to the standard subcutaneous route. https://t.co/A8y8kiRmXv #medRxiv

[Valentina Mazzotta @Vale_Mazzotta]

Proud to share these data on #Mpox and the predictors of its severity and duration from the Italian ICONA cohort.
Clinical and laboratory predictors of mpox severity and duration: an I... https://t.co/SgmL0ozo6E

[@profchloeorkin.bsky.social @profchloeorkin]

🧵 1/1
Colleagues have asked me to share my verbal summation of the ECDC and EACS #mpox outbreak webinar today @ECDC_EU @EACSociety (expertly chaired by @TeyNoori @Esteban09090 @sanjaybhagani )

[Valentina Mazzotta @Vale_Mazzotta]

#mpox group at #ESCMIDGlobal2024
@ChristopheVnDck @asherichia

[@profchloeorkin.bsky.social @profchloeorkin]

Important news:
Monthly CAB+RPV is superior to daily oral therapy in people with suppressed HIV Viral loads and who had struggled to take oral therapy- LATITUDE DSMB has reported https://t.co/Fk5jiKo3jW

[Tulio de Oliveira @Tuliodna]

Release of 8 new genomes of a new lineage of SARS-CoV-2 with > 100 mutations from South Africa. This is probably the most divergence lineage identified this year. In this thread, we highlight some of the characteristics of the new BA.2.X lineage and epidemiology in SA.

[Nature Medicine @NatureMedicine]

Post-hoc multi-omics analysis of a trial comparing a plant-based, #lowfat and animal-based, #ketogenic diets have differential effects on peripheral immune cell frequencies and immune-related gene expression @BelkaidLab @KevinH_PhD @verenalink #nutrition
https://t.co/lR3IIpGAc5

[Nature Medicine @NatureMedicine]

January is #CervicalCancer Awareness Month! We have published 3-year results of the #KENSHE trial, a population-based #RCT reporting the durability of single-dose #HPV #vaccination in young Kenyan women @mgh_id @KEMRI_Kenya
https://t.co/H07qHTopFA

[Valentina Mazzotta @Vale_Mazzotta]

Now published @INMISpallanzani group’s work on immunogenicity and reactogenicity of #MVA vaccination against #Mpox.
@eClinicalMed
https://t.co/hAGTmJcVBu

[Repubblica @repubblica]

La svolta di Aifa: gratis la pillola per prevenire l'Hiv [di Michele Bocci] https://t.co/r0lWVXaL2p

[U.S. FDA @FDA]

Today, FDA amended the EUAs of the Pfizer-BioNTech and Moderna COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals. https://t.co/Cd74KB3n9p
What you need to know. 🧵👇

[NEJM Evidence @NEJMEvidence]

Just published: “Meta-Analysis of Glucocorticoids for Covid-19 Patients Not Receiving Oxygen,” by Remo Daniel Covello, MD, @giovannilandoni, et al. Read the Original Article: https://t.co/Q7R9UAsnyB

#IDTwitter #ARDS #CriticalCare

[Eric Topol @EricTopol]

Here's the graph from today's report, a population with a mean age of 32 years and 17% increased risk over time (~2-year follow-up). This is the youngest adult cohort of the 12 published studies and exhibits the least increase in risk (See Table in above post).

[Valentina Mazzotta @Vale_Mazzotta]

Thanks to @touchINFECTDIS for the interest in the multicentric-phase4-randomized trial MONET (PI @andreaantinori) comparing sotrovimab, tixagevimab/cilgavimab, and nirmatrelvir/ritonavir presented on #ECCMID2023 👇🏻

https://t.co/WTPOe439HC